A Computational Study of Efficient Combinations of FDA-Approved Drugs and Dietary Supplements in Endometrial Cancer
Endometrial cancer (EC) develops in the uterine lining, and in 2024, there will be approximately 67,880 reported cases of uterine cancer in the USA, with 90% of them being EC. Many unfit or elderly cancer patients are unable to undergo standard treatments for EC such as surgery, chemotherapy, or rad...
Saved in:
| Main Authors: | Madhurima Mondal, Aditya Lahiri, Haswanth Vundavilli, Giuseppe del Priore, Norman Peter Reeves, Aniruddha Datta |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IEEE
2024-01-01
|
| Series: | IEEE Access |
| Subjects: | |
| Online Access: | https://ieeexplore.ieee.org/document/10766584/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lenvatinib and pembrolizumab versus platinum doublet chemotherapy as second-line therapy for advanced or recurrent endometrial cancer
by: Yutaka Yoneoka, et al.
Published: (2024-11-01) -
FDA approves leniolisib (Joenja) as the first treatment for APDS: A breaththrough in the field of immunology
by: Muhammad Talha, et al.
Published: (2024-01-01) -
A review of new drugs approved by the food and drug administration in 2022
by: Arjun Swaminathan, et al.
Published: (2023-10-01) -
Nebivolol, an FDA-Approved Drug, Has General Antibacterial and Antibiofilm Effects and Increases <i>Pseudomonas aeruginosa</i> Tolerance to Ciprofloxacin
by: Yael Schlichter Kadosh, et al.
Published: (2024-11-01) -
A Proposed New Path for Management of Health in Inherited Metabolic Disorders Using Engineered Probiotic Bacteria
by: Kurtz CB, et al.
Published: (2024-11-01)